DILI is the principal reason for failure in developing drug candidates. It is the most common reason to withdraw from the market after a drug has been approved for clinical use. However, the current approaches to predicting DILI have not allowed a complete understanding of chemical and biological alerts to identify early compounds associated with DILI events.